Alerts will be sent to your verified email
Verify EmailBETA
|
Beta Drugs
|
Ind-Swift Lab.
|
Venus Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
22.74 % | 14.7 % | 8.87 % |
|
5yr average Equity Multiplier
|
1.82 | 2.17 | 1.32 |
|
5yr Average Asset Turnover Ratio
|
1.03 | 0.66 | 0.96 |
|
5yr Avg Net Profit Margin
|
12.23 % | 16.17 % | 6.91 % |
|
Price to Book
|
0.0 | 0.92 | 2.09 |
|
P/E
|
25.18 | 4.82 | 16.28 |
|
5yr Avg Cash Conversion Cycle
|
7.75 Days | 15.71 Days | 46.96 Days |
|
Inventory Days
|
46.07 Days | 103.91 Days | 75.64 Days |
|
Days Receivable
|
91.57 Days | 105.66 Days | 54.28 Days |
|
Days Payable
|
119.03 Days | 107.02 Days | 58.86 Days |
|
5yr Average Interest Coverage Ratio
|
14.42 | 21.19 | 396.11 |
|
5yr Avg ROCE
|
27.84 % | 12.09 % | 8.42 % |
|
5yr Avg Operating Profit Margin
|
21.76 % | 14.94 % | 10.14 % |
|
5 yr average Debt to Equity
|
0.29 | 0.91 | 0.08 |
|
5yr CAGR Net Profit
|
29.34 % | n/a | -6.01 % |
|
5yr Average Return on Assets
|
12.69 % | 11.49 % | 6.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
64.63 % | 42.99 % | 41.76 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.1 % | 0.99 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Beta Drugs
|
Ind-Swift Lab.
|
Venus Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|